An announcement from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.
Shanghai Henlius Biotech, Inc. announced that the proposed merger by Fosun New Medicine was not approved in the H Shareholders’ Class Meeting, meaning the company will not be privatized and will maintain its listing on the Stock Exchange. Despite the termination of the merger, Fosun Pharma retains its controlling interest, and plans to continue supporting Henlius in enhancing its research and development efforts, thereby strengthening its competitiveness and market presence.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biopharmaceutical industry, focusing on antibody technology. The company serves as a key platform for Fosun Pharma Group in innovative research and development, aiming to expand in domestic and international markets.
YTD Price Performance: -24.56%
Average Trading Volume: 495,790
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$9.72B
Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.